EUVIMEDEUVIMED entdecken
Crossref

Synergistic Nanomedicine Delivering Topoisomerase I Toxin (SN-38) and Inhibitors of Polynucleotide Kinase 3′-Phosphatase (PNKP) for Enhanced Treatment of Colorectal Cancer

Sams M A Sadat iD, Mohammad Reza Vakili, Sara I Abd-El Hafeez, Marco Paladino, Dennis G Hall iD, Michael Weinfeld iD, Afsaneh Lavasanifar iD

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.4c00007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Sams M A Sadat und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta T6G 2R3, Canada. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Irinotecan, Topoisomerase I Inhibitors, Micelles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Canadian Institutes of Health Research, Alberta Cancer Foundation, Ministry of Higher Education and Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsIrinotecanTopoisomerase I InhibitorsMicellesHumansCell Line, TumorAnimalsMiceNanomedicineDrug SynergismDNA Topoisomerases, Type INanoparticlesXenograft Model Antitumor AssaysPolyestersPhosphotransferases (Alcohol Group Acceptor)DNA Repair Enzymes

Stichwörter der Autor:innen

A83B4C63PNKPSN-38chemosensitizercolorectal cancercombination therapymPEO-b-PBCLnanoparticle

Substanzen

IrinotecanTopoisomerase I InhibitorsMicellesPNKP protein, humanDNA Topoisomerases, Type IPolyestersPhosphotransferases (Alcohol Group Acceptor)DNA Repair Enzymes

Autor:innen und Institutionen

  • Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta T6G 2R3, Canada.
  • Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut 71515, Egypt.
  • Department of Chemistry, Faculty of Science, University of Alberta, Edmonton, Alberta T6G 2R3, Canada.
  • Department of Oncology, Cross Cancer Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta T6G 2R3, Canada.
  • Department of Chemical and Material Engineering, University of Alberta, Edmonton, Alberta T6G 2R3, Canada.

ORCID-Profile: Sams M A Sadat, Dennis G Hall, Michael Weinfeld, Afsaneh Lavasanifar

Förderung

  • Canadian Institutes of Health Research
  • Alberta Cancer Foundation
  • Ministry of Higher Education and Scientific Research
  • NanoMedicines Innovation Network

Zitieren

APA

Sadat, S. M. A., Vakili, M. R., Abd-El Hafeez, S. I., Paladino, M., Hall, D. G., Weinfeld, M., & Lavasanifar, A. (2024). Synergistic Nanomedicine Delivering Topoisomerase I Toxin (SN-38) and Inhibitors of Polynucleotide Kinase 3′-Phosphatase (PNKP) for Enhanced Treatment of Colorectal Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00007

Vancouver

Sadat SMA, Vakili MR, Abd-El Hafeez SI, Paladino M, Hall DG, Weinfeld M, et al. Synergistic Nanomedicine Delivering Topoisomerase I Toxin (SN-38) and Inhibitors of Polynucleotide Kinase 3′-Phosphatase (PNKP) for Enhanced Treatment of Colorectal Cancer. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00007

BibTeX
@article{Sadat2024,
  author = {Sadat, Sams M A and Vakili, Mohammad Reza and Abd-El Hafeez, Sara I and Paladino, Marco and Hall, Dennis G and Weinfeld, Michael and Lavasanifar, Afsaneh},
  title = {Synergistic Nanomedicine Delivering Topoisomerase I Toxin (SN-38) and Inhibitors of Polynucleotide Kinase 3′-Phosphatase (PNKP) for Enhanced Treatment of Colorectal Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.4c00007}
}
Kostenlos starten →